Novartis Investigative Site

Pazardzhik 4400

0 studies enrolling now · 6 studies all time

What they study most

Acute Heart Failure, Atherosclerosis, Cardiovascular Disease and Lipoprotein(a), Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction

Studies at this site

• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients — Completed
• Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early